AGB101
small molecule · AgeneBio · APOE as stratifier
Current state
- Status
- Phase 2 — 2 active of 4 tracked studies
- Sponsor
- AgeneBio
- Modality
- small molecule
- Mechanism
- low-dose levetiracetam, APOE4-stratified
- Thesis
- APOE as stratifier
- Record checked
- Verified by a curator
- Last change
- no change event observed since tracking began
- Last reviewed
- (2 days ago)
Trials — 4
| NCT | Title | Phase | Status | Start | Primary completion | N | APOE-strat. |
|---|---|---|---|---|---|---|---|
| NCT03486938 | Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease | PHASE2/PHASE3 | COMPLETED | 164 | no | ||
| NCT05824728 | Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis | PHASE2 | RECRUITING | 30 | no | ||
| NCT05986721 | Clinical Trial of AGB101 for Mild Cognitive Impairment | PHASE2 | WITHDRAWN | 0 | no | ||
| NCT06919926 | Clinical Trial Evaluating the Efficacy of AGB101 for Reducing Hippocampal Overactivity in Older Adults | PHASE2 | RECRUITING | 60 | no |
Publications — 0
No linked publication. Nothing has been resolved to this therapeutic in Europe PMC or OpenAlex. Where nobody has checked the record yet, this usually means the identifier is used inconsistently in the literature rather than that no work exists.
Change history — 0
No changes detected for AGB101 as of the snapshot taken .
This is not the same as nothing having happened. The oldest source in this snapshot last succeeded (2 days ago), and registry and filing data lag the events they describe. See methodology.